title: MACULAR CHOROIDAL VOLUME CHANGES AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
abstract: OBJECTIVE
  To evaluate the effect of intravitreal bevacizumab on the macular choroidal volume and the subfoveal choroidal thickness in treatment naïve eyes with exudative age-related macular degeneration.
  
  
  METHODS
  The macular choroidal volume and the subfoveal choroidal thickness were measured using enhanced depth imaging optical coherence tomography. After a screening examination, each patient received 3 monthly intravitreal injections of 1.25 mg bevacizumab. One month after the third injection was a final assessment.
  
  
  RESULTS
  Forty-seven patients with a mean age of 80 ± 6.4 years were included. The macular choroidal volume decreased significantly from median 4.1 mm (interquartile range 3.4-5.9) to median 3.9 mm (interquartile range 3.1-5.6) between the baseline and final examination (difference -0.46 mm, 95% confidence interval: -0.57 to 0.35, P < 0.001). Similarly, subfoveal choroidal thickness had decreased from 157.0 μm (interquartile range 116.0-244.5) at baseline to 139.0 μm (interquartile range 102.5-212.0) at the final examination (P < 0.001). Both parameters macular choroidal volume at baseline and subfoveal choroidal thickness at baseline were not associated with the response to treatment.
  
  
  CONCLUSIONS
  The macular choroidal volume and the subfoveal choroidal thickness decreased significantly after 3 monthly bevacizumab injections for exudative age-related macular degeneration.
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: Stefan
authors.initials: S
authors.lastname: Palkovits
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: Gerald
authors.initials: G
authors.lastname: Seidel
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: Laura
authors.initials: L
authors.lastname: Pertl
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: Eva M
authors.initials: EM
authors.lastname: Malle
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: Silke
authors.initials: S
authors.lastname: Hausberger
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: Johanna
authors.initials: J
authors.lastname: Makk
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: Christoph
authors.initials: C
authors.lastname: Singer
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: Julia
authors.initials: J
authors.lastname: Osterholt
authors.affiliation: Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
authors.forename: Sereina A
authors.initials: SA
authors.lastname: Herzog
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: Anton
authors.initials: A
authors.lastname: Haas
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: Martin
authors.initials: M
authors.lastname: Weger
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D002829:Choroid / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005451:Fluorescein Angiography / Q000379:methods*; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000473:pathology*; D008875:Middle Aged; D009929:Organ Size; D011446:Prospective Studies; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D013997:Time Factors; D041623:Tomography, Optical Coherence / Q000379:methods*; D016896:Treatment Outcome; D014792:Visual Acuity; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor